{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T06:43:36Z","timestamp":1768027416857,"version":"3.49.0"},"reference-count":9,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"vor","delay-in-days":374,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.medj.2024.10.002","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T10:38:47Z","timestamp":1736505527000},"page":"100525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The climb toward intracranial efficacy: Zorifertinib in EGFR-mutant NSCLC with CNS metastases in the EVEREST trial"],"prefix":"10.1016","volume":"6","author":[{"given":"Meaghan","family":"Roy-O\u2019Reilly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Rogawski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2024.10.002_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2024.09.002","article-title":"First-line zorifertinib for EGFR-mutant NSCLC with CNS metastases: The phase 3 EVEREST trial","volume":"6","author":"Zhou","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.medj.2024.10.002_bib2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.lungcan.2016.04.004","article-title":"EGFR mutation status on brain metastases from non-small cell lung cancer","volume":"96","author":"Hsu","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.medj.2024.10.002_bib3","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00280-012-1929-4","article-title":"Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer","volume":"70","author":"Togashi","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.medj.2024.10.002_bib4","doi-asserted-by":"crossref","first-page":"6168","DOI":"10.1158\/1078-0432.CCR-20-2081","article-title":"Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M-positive Non-Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study","volume":"26","author":"Xing","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2024.10.002_bib5","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaoncol.2024.2640","article-title":"Lazertinib in EGFR-Variant Non-Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors: A Nonrandomized Controlled Trial","volume":"10","author":"Hong","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.medj.2024.10.002_bib6","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S2213-2600(17)30378-8","article-title":"Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study","volume":"5","author":"Ahn","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.medj.2024.10.002_bib9","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1200\/JCO.2018.78.3118","article-title":"CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR -Mutated Advanced Non\u2013Small-Cell Lung Cancer","volume":"36","author":"Reungwetwattana","year":"2018","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.medj.2024.10.002_bib7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.10.002_bib8","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N.\u00a0Engl. J. Med."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634024003817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634024003817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T03:03:55Z","timestamp":1768014235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634024003817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2666634024003817"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2024.10.002","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The climb toward intracranial efficacy: Zorifertinib in EGFR-mutant NSCLC with CNS metastases in the EVEREST trial","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2024.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2024.09.002","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100525"}}